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Abstract  
 
Introduction: Computerised respiratory Sounds (CRS) are closely related to the 
movement of air within the tracheobronchial tree, and are promising outcome 
measures in patients with chronic obstructive pulmonary disease (COPD). However, 
CRS measurement properties have been poorly tested. 
Objective: To assess the reliability, validity, and the minimal detectable changes 
(MDC) of CRS in patients with stable COPD. 
Methods: Fifty patients (36♂, 67.26±9.31y, FEV1 49.52±19.67%predicted) were 
enrolled. CRS were recorded simultaneously at seven anatomic locations (trachea; 
right and left anterior, lateral and posterior chest). The number of crackles, wheeze 
occupation rate (%Wh), median frequency (F50) and maximum intensity (Imax) were 
processed using validated algorithms. Within-day and between-days reliability, 
criterion and construct validity, validity to predict exacerbations and MDC were 
established. 
Results: CRS presented moderate-to-excellent within-day reliability (ICC1,3≥0.51; 
p<0.05) and moderate-to-good between-days reliability (ICC1,2≥0.47; p<0.05) for most 
locations. Low-to-moderate correlations with FEV1%predicted were found (-0.53<rs<-
0.28; p<0.05), and the inspiratory number of crackles were the best discriminator 
between mild-to-moderate and severe-to-very severe airflow limitations (area under 
the curve>0.78). CRS correlated poorly with patient-reported outcomes (rs<0.48; 
p<0.05) and did not predict exacerbations. Inspiratory number of crackles at posterior 
right chest, inspiratory F50 at trachea and anterior left chest and expiratory Imax at 
anterior right chest were simultaneously reliable and valid, and their MDC were 2.41, 
55.27, 29.55 and 3.98, respectively. 
Conclusion: CRS are reliable and valid. Their use, integrated with other clinical and 
patient-reported measures, may fill the gap of assessing small airways and contribute 
towards a patient’s comprehensive evaluation. 
 
Keywords: Reproducibility of results; Pulmonary Disease, Chronic Obstructive; 
Respiratory Sounds; Spirometry  
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Introduction 
Chronic Obstructive Pulmonary Disease (COPD) is characterized by persistent 
respiratory symptoms and airflow limitation due to smaller airway and/or alveolar 
abnormalities (1). Although diagnosis and monitoring of airflow limitation is usually 
performed by spirometry (gold standard test of lung function) (1), its usefulness to 
assess interventions has been questioned, as it mainly assesses large airways (2), 
changes in response to treatments are small (3,4), and correlates poorly with patient-
reported outcomes (5). Thus, international Respiratory Societies have been stressing 
the need to validate instruments that can express peripheral respiratory function, 
assess patient’s response to interventions and correlate with patient-reported 
outcomes (6). 
 
Computerised respiratory sounds are a simple, objective, and non-invasive outcome 
measure that are directly related to the movement of air within the tracheobronchial 
tree (7). Therefore, changes in airway and/or alveolar mechanisms may be primarily 
detected by changes in the frequency/intensity of normal respiratory sounds and by 
the presence of adventitious respiratory sounds (i.e., crackles and wheezes) (7). This 
theoretical potential of computerised respiratory sounds to be used as an outcome 
measure has been motivating research of their characteristics and measurement 
properties (8-10). A recent study in stable patients with COPD has shown that 
respiratory sounds have adequate within-day reliability (10). However, other 
measurement properties need to be studied before computerised respiratory sounds 
utilisation can be recommended for clinical practice (11). Between-days reliability and 
validity are crucial measurement properties of an outcome measure which, according 
to the authors’ best knowledge, have never been explored in computerised respiratory 
sounds, hindering the interpretation of its actual usefulness to assess lung function 
(validity) and its repeatability during prolonged stable phases (reliability). 
 
This study aimed to evaluate the between-days reliability, criterion, construct and 
predictive validity of computerised respiratory sounds in patients with COPD. The 
authors hypothesised that computerised respiratory sounds would present i) 
significant and moderate between-days reliability; ii) significant, negative and low-to-
moderate correlations with lung function; iii) significant, negative and moderate 
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correlations with patient-reported outcome measures and iv) significant ability to 
predict acute exacerbations of COPD up to 1 year. 
 
Materials and Methods 
Study design 
A cross-sectional study was conducted. Reliability and validity were explored, 
described and interpreted following the COnsensus-based Standards for the selection 
of health status Measurement Instruments (COSMIN) guidelines (11,12). 
 
Sample size 
The sample size was determined according to the COSMIN guidelines, which have 
established that a study with good methodological quality should enrol a minimum of 
50 participants (12). 
 
Participants 
Outpatients with stable COPD were recruited from a central hospital between January 
2016 and 2017. Inclusion criteria were diagnosis of COPD according to the Global 
Initiative for Chronic Obstructive Lung Disease (GOLD) criteria (1) and clinical stability 
for one month prior to the study (i.e., no hospital admissions, exacerbations as defined 
by GOLD, or changes in respiratory system medication). Patients were excluded if 
they had severe co-existing respiratory, neurological, cardiac, musculoskeletal, or 
psychiatric impairments. Approvals for this study were obtained from the ethics 
committee of the Central Hospital (13NOV’1514:40065682) and National Data 
Protection Committee (8828/2016). Eligible patients were identified by clinicians and 
then contacted by the researchers, who explained the purpose of the study and asked 
about their willingness to participate. When patients agreed to participate, an 
appointment with the researchers was scheduled and written informed consent was 
obtained. 
 
Data collection 
Participants were asked to attend to two testing sessions with a five to seven days 
interval. In the first session, patients completed a questionnaire with 
sociodemographic (age, gender) and health-related (smoking status, exacerbations in 
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the previous year, symptoms and impact of the disease) information. Height and 
weight were recorded to calculate the body mass index (BMI).  
 
Smoking status was evaluated with a 2-question survey on current and previous 
smoking habits. Cough and wheezing were assessed through a numerical scale (NS) 
in which the patient reported the severity of the symptoms in the previous 24h. The 
NS is reliable (Intraclass correlation coefficient, ICC from 0.54 to 0.86) and valid to 
assess symptoms in patients with respiratory diseases (13,14). Dyspnoea was 
collected using the modified Medical Research Council (mMRC) dyspnoea scale (15). 
The patients read the 5-point mMRC scale and pointed the grade (0 to 4) that most 
closely matched his or her breathlessness. Higher scores represent more 
breathlessness. The mMRC has shown to be a reliable (ICC=0.82) (16) and valid 
measure of disability related with dyspnoea (17). Impact of the disease was collected 
with the COPD Assessment Test (CAT). The CAT is a reliable (Cronbach α=0.88) and 
valid self-administered 8-question questionnaire, which allows the assessment of the 
impact of COPD on health status within only a few minutes (18). Higher scores 
represent higher impact of COPD. 
 
Then, three respiratory sounds recordings were performed with air-coupled electret 
microphones (C 417 PP, AKG Acoustics GmbH, Vienna, Austria) (19) following the 
computerised respiratory sound analysis (CORSA) guidelines for short-term 
acquisitions (20). Finally, lung function was assessed with a portable spirometer 
(MicroLab 3535, CareFusion, Kent, UK) according to the guidelines (21). 
 
In the second session, only respiratory sounds were recorded. Effort was made to 
keep all factors associated with the testing sessions consistent, specifically the time 
of day, location of the sessions, chest locations of the microphones and order of 
testing.  
 
Additionally, participants were telephoned every three months, up to one year of their 
initial assessment, to gather information about the occurrence of an exacerbation (1). 
 
Respiratory sound recordings  
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Recordings were performed simultaneously at seven anatomic locations (trachea and 
right and left anterior upper, lateral middle, and posterior lower chest) (20). The 
recording system included eight air-coupled electret microphones, a multi-channel 
audio interface (AudioBox 1818 VSL, PreSonus, Florida, USA), and a laptop computer 
running LungSounds@UA interface (22). Seven microphones, mounted in couplers 
made Teflon (23), were attached on the participant’s skin with double-faced adhesive 
tapes (Double Stick Discs, 3M Littmann, Cheshire, UK), and one microphone was 
placed closed to the patient to record the background noise. The analog sound signals 
acquired were amplified and converted to digital by the audio interface with a 24-bit 
resolution and a sampling rate of 44.1 kHz. Each data acquisition session lasted for 
20-s (24) and the recorded data were later converted to .wav format.  
 
Signal processing 
Respiratory sound files were processed by automatic algorithms implemented in 
Matlab R2009a (MathWorks, Natick, Massachusetts). Data were obtained for number 
of crackles, occupation rate of wheezes (%Wh), median frequency (F50) and 
maximum intensity (Imax) per respiratory phase (i.e., inspiration and expiration) and 
per chest location.  
Number of crackles per respiratory phase was calculated using equation 1: 
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑟𝑎𝑐𝑘𝑙𝑒𝑠 =
Sum of crackles per respiratory phase
Total number of respiratory phases
  (1) 
 
Occupation rate of wheezes (%Wh) was calculated through equations 2 and 3:  
𝑅𝑎𝑡𝑒 𝑜𝑓 𝑒𝑎𝑐ℎ 𝑤ℎ𝑒𝑒𝑧𝑒 =
Duration of wheeze in the respiratory phase
Total duration of the respiratory phase
 X 100 (2) 
 
%Wh = ∑(rate of each wheeze in the respiratory phase) (3) 
 
Median frequency (F50) and maximum intensity (Imax) were calculated following the 
methodology proposed by Pasterkamp, Powell, Sanchez (25) after excluding 
adventitious respiratory sounds in each file. F50 and Imax were analysed within a 
frequency band of 300–600 Hz, as this has been indicated as the most representative 
frequency band for patients with respiratory diseases (26,27). All analyses were 
checked by two respiratory experts and the average respiratory sound spectra and 
background noise were plotted to ensure the quality of sound recordings. Background 
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noise was closely superimposed to respiratory sound intensity at lateral chest; hence, 
these locations were excluded from further analyses. The average spectra of normal 
respiratory sounds at trachea, anterior, lateral and posterior chest can be found in the 
supplementary material and a detailed description of the signal processing is provided 
elsewhere (28). 
 
Statistical Analysis 
Statistical analyses were performed using IBM SPSS Statistics version 24.0 (IBM 
Corporation, Armonk, NY, USA) and plots were created using GraphPad Prism version 
5.01 (GraphPad Software, Inc., La Jolla, CA, USA). The level of significance was set 
at 0.05. Descriptive statistics were used to describe the sample. Characteristics were 
compared between patients at stages I-II and III-IV of airflow limitation (1), using 
independent t-tests for normally distributed data (age, BMI, and lung function), Mann-
Whitney U-tests for ordinal data (mMRC, CAT and NS), and Chi-square tests for 
categorical data (gender, smoking status, number of exacerbations/year). 
 
Reliability 
Within- and between-days reliability were determined. Relative and absolute reliability 
were calculated with the ICC and the Bland and Altman method, respectively (29). 
Within-day reliability was computed using the ICC equation (1, k), where k=3 
corresponds to the three recordings performed in session 1. The Bland and Altman 
method assesses the agreement between two sets of measures (30); thus, random 
numbers were generated in MATLAB to delete one recording. Between-days reliability 
was computed using the ICC equation (1, k), where k=2 corresponds to the two 
recordings used (one from session 1 and one from session 2). Bland and Altman plots 
were also created to analyse the distribution of results from session 1 and 2. ICC was 
interpreted as excellent (>0.75), moderate-to-good (0.4–0.75), or poor (<0.4) (31). 
 
Validity 
Criterion validity was assessed by analysing the degree to which respiratory sounds 
correlated with lung function (i.e., percent predicted forced expiratory volume in one 
second, FEV1%predicted) using Spearman's rank correlation coefficient. The strength 
of the correlations was interpreted as negligible (i.e., 0-0.30); low (0.31-0.50), 
moderate (0.51-0.70), high (0.71-0.90) or very high (0.91-1) (32). 
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Receiver operating characteristic (ROC) analysis was used to assess the ability of 
respiratory sounds to differentiate between patients’ airflow limitation severity. The 
ROC analysis only allows to plot the performance of a binary classification, thus, 
patients classified in the GOLD criteria as I and II were labelled as mild-to-moderate 
airflow limitation and patients classified as III and IV were labelled as severe-to-very 
severe airflow limitation. The cut-off for each respiratory sound parameter was chosen 
as the point where the sensitivity and specificity were simultaneously maximized. Area 
under the curves (AUC) and the 95% confidence interval were determined. AUC was 
interpreted as: AUC=0.5 no discrimination; 0.7≤AUC<0.8 acceptable discrimination; 
0.8≤AUC<0.9 excellent discrimination and AUC≥0.9 outstanding discrimination (33). 
 
Construct validity was assessed by examining the relationship between respiratory 
sounds, NS, mMRC and CAT using Spearman's rank correlation coefficient. 
 
Predictive validity up to 12 months exacerbations were explored with ROC analysis 
and the inﬂuence of independent predictors (i.e., no. of crackles, %Wh, F50 and Imax) 
on the time until the first exacerbation was analysed by univariate and multivariate Cox 
regression analyses. 
 
Minimal detectable change 
Minimal detectable changes (MDC) were only computed for respiratory sound 
parameters and locations that have simultaneously shown adequate between-days 
reliability (ICC>0.75) and validity (significant correlations with FEV1%predicted).  
To determine the MDC, first, the standard error of measurement (SEM) was calculated 
using the equation 4: 
𝑆𝐸𝑀 = 𝑆𝐷 √(1 − 𝐼𝐶𝐶1,2 ) (4) 
where SD is the standard deviation of the scores obtained from all participants and 
ICC is the between-days reliability coefficient. 
 
The MDC at the 95% level of confidence (MDC95) was calculated as follows (equation 
5): 
𝑀𝐷𝐶95 = 𝑆𝐸𝑀 × 1.96 × √2 (5) 
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The MDC was also expressed as a percentage (MDC%), defined as (equation 6): 
𝑀𝐷𝐶% = (𝑀𝐷𝐶95 𝑚𝑒𝑎𝑛) × 100⁄  (6) 
where “mean” is the mean of the scores obtained in the two testing sessions. A MDC% 
below 30% was considered acceptable (34). 
 
Results 
Participants 
Fifty-eight patients were contacted and invited to participate in the study. However, 
seven refused to participate, as they did not perceive the study as relevant (n=5) or 
had family constrains to their participation (n=2), and one did not complete the 
assessment. Therefore, 50 participants (36 males) were enrolled in the study. 
Participants’ characteristics are summarized in Table 1. 
 
Please insert Table 1 here 
 
 
Reliability 
Adventitious respiratory sounds presented excellent within-day reliability 
(ICC1,3>0.75); except at trachea in both respiratory phases (0.57<ICC1,3<0.74) and at 
anterior chest during expiration (0.65<ICC1,3<0.73) for the number of crackles, and at 
anterior right chest during both phases (0.51<ICC1,3<0.68) for %Wh. F50 and Imax 
also presented excellent reliability, except at anterior right chest during inspiration 
(0.51<ICC1,3<0.73). Absolute reliability showed no systematic bias for any location 
and/or respiratory phase according to the Bland and Altman plots. Further information 
of within-day reliability is on supplementary material. 
 
Table 2 presents the relative between-days reliability. During inspiration, crackles and 
wheezes showed moderate-to-good or excellent reliability (0.48≤ICC1,2≤0.96; p<0.05) 
at anterior and posterior chest. F50 and Imax showed moderate-to-good or excellent 
reliability (ICC1,2>0.45 and ICC1,2≥0.60, respectively; p<0.05), except at posterior left 
chest (ICC1,2<0.41; p>0.05). During expiration, %Wh and normal respiratory sounds 
were reliable at trachea and at the anterior chest (ICC1,2>0.54; p<0.05), and the 
number of crackles were only reliable at trachea (ICC1,2=0.79; p<0.05).  
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Please insert Table 2 here 
 
Good absolute between-days reliability with no systematic bias was found in the Bland 
and Altman plots for number of crackles and normal respiratory sounds. However, 
large limits of agreement were found at trachea for all respiratory sound parameters 
and for %Wh in all locations, especially during expiration. Figure 1 and 2 shows the 
Bland-Altman plots obtained at posterior right and left chest, respectively. The 
remaining plots can be found in the supplementary material. 
 
Please insert Figure 1 and Figure 2 here 
 
Validity 
Concerning criterion validity, significant low-to-moderate negative correlations (-
0.53<rs<-0.32; p<0.05) between FEV1%predicted and adventitious respiratory sounds 
were found, especially for the number of crackles during inspiration. Significant 
correlations were also found for normal respiratory sounds, being negative for 
inspiratory F50 and positive for Imax, especially during inspiration. Table 3 presents 
the correlations between FEV1%predicted and computerised respiratory sounds. 
 
Please insert Table 3 here 
 
AUCs of all variables analysed ranged from 0.27 to 0.81, indicating “no discrimination” 
to “acceptable discrimination”. Higher AUCs were found for inspiratory number of 
crackles recorded at posterior right (AUC=0.78; 95%CI=0.51-1.00; p<0.001) and left 
(AUC=0.81; 95%CI=0.68-0.93; p<0.001) chest (Figure 3). To differentiate between 
participants with mild-to-moderate from participants with severe-to-very severe airflow 
limitation, cutoff points of 0.1 (sensitivity=81%; specificity=71%) and of 0.5 
(sensitivity=74%; specificity=80%) for the mean number of crackles at posterior right 
and left chest, respectively, were identified. Results from the ROC analysis of all 
computerised respiratory sounds are in the supplementary material. 
 
Please insert Figure 3 here 
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Concerning construct validity, significant low positive (rs<0.48; p<0.05) correlations 
were found between patient-reported outcome measures and computerised 
respiratory sounds. Values for all correlations are in the supplementary material. 
 
Concerning predictive validity, both adventitious and normal respiratory sounds 
showed no ability to predict exacerbations up to one year, with AUCs ranging from 
0.00 to 0.58 (p>0.05). None of the computerised respiratory sound parameters were 
predictors of the time until the first exacerbation (p>0.05; hazard ratios between 0.95 
and 1.04). 
 
Minimal detectable change 
The respiratory sounds parameters presenting adequate reliability and validity were 
inspiratory number of crackles at posterior right chest, inspiratory F50 at trachea and 
anterior left chest, and expiratory Imax at anterior right chest. The MDC95 was 2.41 
(SEM=0.87; MDC%=175.38%), 55.27 (SEM=19.94; MDC%=41.22%), 29.55 
(SEM=10.66; MDC%=31.86%) and 3.98 (SEM=1.43; MDC%=35.47%) for number of 
crackles, F50 at trachea, F50 at anterior left chest and Imax, respectively. 
 
Discussion 
To the authors’ best knowledge, this is the first study describing computerised 
respiratory sounds reliability and validity according to the COSMIM guidelines. The 
main findings indicate that respiratory sounds i) present moderate-to-excellent within-
day reliability and moderate-to-good between-days reliability; ii) are valid to express 
lung function, especially inspiratory number of crackles at posterior chest; iii) correlate 
poorly with patient-reported outcome measures; iv) do not predict COPD 
exacerbations and v) present high values of MDC. 
 
Moderate-to-excellent within-day reliability was found for all respiratory sound 
parameters, which is in line with data previously reported (ICC1,3 from 0.66 to 0.89) 
(10). Regarding to between-days reliability, slightly lower values were found. This was 
expected, as it is known that better reliability is achieved when repeated tests are 
performed within short periods of time (35). The number of inspiratory crackles, 
recorded at posterior chest, and inspiratory and expiratory %Wh, recorded at anterior 
chest, were the most reliable parameters. It is known that COPD is characterized by 
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changes in airflow mechanics targeting mainly the smaller airways (1), thus inspiratory 
crackles at posterior regions have been indicated as the most common and persistent 
finding in these patients (10,36). Wheezes are also a usual characteristic of patients 
with bronchial obstruction (37). In the present study, inspiratory wheezes were slightly 
more reliable than expiratory wheezes, which may be explained by their genesis. 
Patients with COPD usually experience expiratory low frequency wheezes (also 
known as rhonchi) in upper airways that are generally produced by increased sputum 
and are easily removed by cough (36,38). On the other hand, inspiratory wheezes are 
more related with severe airway obstruction (37), which characterizes most of our 
sample, and thus are more difficult to change with respiratory manoeuvres.  
 
Similar to what has been previously described for within-day reliability (10), the 
agreement assessed with the Bland-Altman method was found to be acceptable for 
mean number of crackles and normal respiratory sounds intensity. However, high 
limits of agreement were found at trachea and expiratory wheezes, possibly due to 
their dependence on airflow and respiratory manoeuvres. Therefore, this anatomic 
location and respiratory sound parameter may not be suitable to use in interventions 
studies of patients with stable COPD. 
 
Overall, respiratory sounds showed low-to-moderate correlations with 
FEV1%predicted, being the strongest correlations found for the number of crackles at 
posterior regions. The presence of inspiratory crackles at the posterior chest also 
showed to be discriminative of participants with more and less severe airflow limitation. 
FEV1 mainly expresses obstruction in larger airways (2), while COPD pathogenesis 
primarily targets small airways (1). On the other hand, crackles are an acoustic 
phenomenon that, when heard over distal lung regions, are associated with 
inflammation or oedema (39) of smaller airways. Thus, whilst high correlations 
between these outcome measures would not be expected, the significant correlations 
found, highlight crackles potential to indicate peripheral airway obstruction in patients 
with COPD.  
 
Significant and lower correlations were also found between FEV1%predicted and Imax 
at the anterior chest. Similar results have been reported (40) and might be related with 
a shift of regional ventilation from the lower- to upper-lung locations as a function of 
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the degree of hyperinflation presented in more severe COPD patients. This type of 
hyperinflation can be reversed with therapy (41) and inspiratory maximum intensity 
recorded at the anterior chest may be an adequate outcome measure to assess these 
changes. F50 has been the respiratory sound parameter most described as related 
with lung function (42-44) however, in this study only poor correlations were found 
between F50 and FEV1. Different methodologies used across studies, i.e., no 
additional maneuvers or forced expiratory maneuvers or chemical substances that 
cause airway obstruction during respiratory sound recordings, might explain this 
incongruence. Nevertheless, our results mimic those from Malmberg et al., (1995) (45) 
where a similar protocol has been used. Therefore, protocol standardisation to record 
respiratory sounds is needed to advance knowledge in this field. 
 
Regarding construct validity, significant and negative, although low, correlations were 
found between respiratory sounds and patient-reported outcome measures. Similar  
results have been found for FEV1 (0.14<r<0.41) (5) and for respiratory sounds 
(0.33<r<0.57) (46) in previous studies and further confirms that clinical outcome 
measures significantly differ from the individuals’ experience of the disease effects on 
health status and hence, should not be used isolated (47). 
 
Respiratory sounds presented no ability to predict exacerbations up to one year after 
the baseline assessment. Although changes in the tracheobronchial tree are closely 
related with changes in respiratory acoustics (48), such associations are likely to be 
unravelled in time periods close to exacerbations, when the beginning of the 
inflammatory and/or infectious process has occurred. Additionally, although COPD is 
mainly characterised by changes in smaller airways, COPD exacerbations are 
frequently triggered by upper respiratory tract infections (49), thus it is reasonable that 
predictions of these events are better detected by changes in larger airways. Indeed, 
recent studies have shown that computerised respiratory sounds, recorded at trachea, 
have potential to predict exacerbations in the short term (i.e., 5 days ahead of medical 
attention), however such predictions have been determined based on complex 
analysis (principal component analysis), that cannot be easily understood and 
applicable by clinicians in clinical practice (50). Our results have shown that F50 and 
Imax recorded at upper anatomical locations are valid and reliable parameters and 
can be more easily determined or even perceived by clinicians during auscultation. 
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Thus, we recommend future studies on COPD telemonitoring to explore the efficacy 
of these normal respiratory parameters to early detect exacerbations. 
High MDC values were found for all respiratory sound parameters which might be 
related with patients’ high inter-variability, as reported in previous studies (10). These 
results highlight the importance of supporting health-care professionals’ clinical 
decisions in the interpretation of respiratory sound changes at an individual level and 
in combination with other patient-reported outcome measures. Nevertheless, this was 
the first study to calculate MDC for respiratory sounds and provides a valuable cut-off 
point to represent minimum detectable change in repeated measures beyond the 
threshold of error. 
 
Limitations 
This study has some potential limitations that need to be discussed. Flows and/or 
volumes were not controlled during respiratory sounds recordings and it is known that 
respiratory sound acoustics depends on volume and rate of respiratory maneuvers 
(48). However, this can be arguable for the purposes of this study as it has been 
previously demonstrated that even without airflow control, respiratory sounds present 
adequate reliability (ICC>0.70) and are almost as reliable as during recordings at 
controlled flows (10). Moreover, this study was designed to be as close to clinical 
practice as possible, and currently, equipment for airflow monitoring is expensive, little 
portable and requires trained professionals for its interpretation, which hinders its use 
in such settings.  
This study followed the COSMIN methodological recommendations to test the 
suitability of an outcome measure to be implemented in the clinical practice. The 
COSMIN was originally developed for health-related, patient-reported outcome 
measures, such as questionnaires (11). Therefore, the application of the COSMIN as 
a tool for guiding methodology of studies testing clinical outcome measures can be 
questioned. Nonetheless, in the absence of guidelines specifically designed to 
conduct such studies, the COSMIN is indicated as an adequate alternative tool (51). 
 
Conclusion 
The number of crackles recorded at posterior locations and the normal respiratory 
sounds recorded at trachea and anterior regions are reliable and valid parameters to 
assess and monitor patients with stable COPD. Nonetheless, results from criterion and 
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construct validity showed that computerised respiratory sounds should not be used 
isolated, but rather integrated with other clinical and patient reported outcome 
measures, as they may fill the gap of assessing small airways and contribute towards 
a patient’s comprehensive evaluation. 
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Figure legend 
Figure 1. Bland and Altman plots of number of crackles and wheeze occupation rate (%Wh) 
collected at session 1 (S1) and session 2 (S2) at posterior right and left chest. Solid lines represent 
the zero value dashed lines show the associated bias and 95% upper (ULA) and lower (LLA) 
limits of agreement. 
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Figure 2. Bland and Altman plots of median frequency (F50) and maximum intensity (Imax) 
collected at session 1 (S1) and session 2 (S2) at posterior right and left chest. Solid lines represent 
the zero value dashed lines show the associated bias and 95% upper (ULA) and lower (LLA) 
limits of agreement. 
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Figure 3. Receiver operator characteristics (ROC) of the inspiratory number of crackles at 
posterior right and left chest to differentiate between participants with mild-to-moderate airflow 
limitation and participants with severe-to-very severe airflow limitation. 
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Tables and captions 
Table 1. Sample characterization. 
 
Characteristics Total 
(n=50) 
GOLD stages 
I-II (n=21) 
GOLD stages 
III-IV (n=29) 
p-value 
Age, years 67.26±9.31 67.29±11.22 67.24±7.87 0.987 
Gender (male), n(%) 36 (72) 13 (62) 23 (79) 0.213 
BMI, kg/m2 27.26±8.22 29.93±11.26 25.32±4.28 0.049* 
Smoking status, n(%) 
Current 
Former 
Never 
 
7 (14) 
26 (52) 
17 (34) 
 
5 (24) 
7 (33) 
9 (43) 
 
2 (7) 
19 (66) 
8 (28) 
0.056 
Packs/year, M[IQR] 50 [32-77] 48 [24-54] 50 [33-90] 0.294 
Exacerbations/year, n(%) 
0 
1 
≥2 
 
18 (36) 
9 (18) 
23 (46) 
 
6 (29) 
4 (19) 
11 (52) 
 
12 (41) 
5 (18) 
12 (41) 
0.638 
FEV1, L 1.24±0.53 1.65±0.53 0.95±0.28 <0.001* 
FEV1, %predicted 49.52±19.67 69.10±10.65 35.34±10.04 <0.001* 
FEV1/FVC, % 49.76±13.24 58.71±8.65 43.28±12.24 <0.001* 
GOLD stages, n(%)     
I 3 (6)    
II 18 (36)    
III 21 (42)    
IV 8 (16)    
CAT, M[IQR] 13 [8-21] 12 [9-18] 14 [7-23] 0.582 
mMRC, M[IQR] 2 [1-2] 1 [1-2] 2 [1-3] 0.004* 
NS, M[IQR]     
Cough 1 [0-3] 2 [0-5] 1 [0-3] 0.233 
Wheezing 2 [0-4] 2 [0-3] 3 [0-5] 0.236 
*p<0.05 
Values are presented as mean±standard deviation, unless otherwise stated. 
Legend: BMI, body mass index; CAT, COPD Assessment Test; FEV1, forced expiratory volume 
in one second; FVC, forced vital capacity; GOLD, Global Initiative for Chronic Obstructive Lung 
Disease; IQR, interquartile range; M, median; mMRC, Modiﬁed British Medical Research Council 
questionnaire; SD, standard deviation; NS, numerical scale. 
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Table 2. Between-days reliability (ICC1,2) for normal and adventitious respiratory sounds. 
 
 Inspiration Expiration 
 No. crackles %Wh F50 Imax No. crackles %Wh F50 Imax 
Trachea 0.38 
[-0.12-0.69] 
0.62* 
[0.31-0.79] 
0.79* 
[0.62-0.83] 
0.62* 
[0.32-0.79] 
0.79* 
[0.62-0.88] 
0.69* 
[0.44-0.83] 
0.71* 
[0.47-0.84] 
0.84* 
[0.72-0.91] 
Anterior 
right  
0.63* 
[0.33-0.796] 
0.92* 
[0.86-0.96] 
0.51* 
[0.12-0.73] 
0.60* 
[0.27-0.78] 
0.44 
[-0.02-0.69] 
0.54* 
[0.16-0.74] 
0.54* 
[0.16-0.75] 
0.78* 
[0.60-0.88] 
Anterior 
left 
0.88* 
[0.78-0.94] 
0.96* 
[0.92-0.96] 
0.86* 
[0.73-0.93] 
0.73* 
[0.48-0.86] 
0.36 
[-0.22-0.66] 
0.70* 
[0.43-0.85] 
0.75* 
[0.52-0.87] 
0.60* 
[0.24-0.79] 
Posterior 
right  
0.79* 
[0.62-0.89] 
0.57* 
[0.21-0.76] 
0.47* 
[0.03-0.71] 
0.65* 
[0.35-0.81] 
0.42 
[-0.05-0.68] 
-0.01 
[-0.85-0.45] 
0.39 
[-0.11-0.66] 
0.43 
[-0.03-0.69] 
Posterior 
left  
0.74* 
[0.52-0.86] 
0.48* 
[0.04-0.72] 
0.41 
[-0.10-0.68] 
0.15 
[-0.58-0.54] 
0.25 
[-0.39-0.59] 
0.07 
[-0.73-0.50] 
0.31 
[-0.29-0.63] 
0.07 
[-0.72-0.50] 
*p<0.05 
Values are presented as ICC1,2 [95% confidence interval]. 
Legend: %Wh, wheeze occupation rate; F50, median frequency; Imax, maximum intensity. 
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Table 3. Correlations between lung function (FEV1 %predicted) and computerised respiratory sounds. 
 
 Inspiration Expiration 
F
E
V
1  %
p
re
d
ic
te
d
 
 No. crackles %wh F50 Imax No. crackles %wh F50 Imax 
Trachea 
 
rs=-0.07 rs=-0.09 rs=-0.35* rs=0.28* rs=-0.20 rs=-0.37* rs=-0.18 rs=0.26 
Anterior 
right  
rs=-0.11 rs=-0.09 rs=-0.18 rs=0.32* rs=-0.16 rs=-0.20 rs=0.04 rs=0.32* 
Anterior 
left  
rs=-0.42* rs=-0.13 rs=-0.37* rs=0.36* rs=-0.53* rs=-0.18 rs=0.04 rs=0.03 
Posterior 
right  
rs=-0.44* rs=-0.23 rs=0.06 rs=0.23 rs=-0.11 rs=-0.21 rs=0.02 rs=0.28 
Posterior 
Left  
rs=-0.42* rs=-0.22 rs=0.02 rs=0.07 rs=-0.16 rs=-0.12 rs=0.14 rs=-0.08 
*p<0.05 
Values are presented as Spearman’s correlations. 
Legend: %wh, wheeze occupation rate; F50, median frequency; Imax, maximum intensity. 
 
 
 
